This trial is testing if adding darolutamide to ADT (a treatment to reduce testosterone levels) is more effective than ADT alone in treating high-risk prostate cancer.
1 Primary · 9 Secondary · Reporting Duration: From randomization to any of the MFS events, pelvic lymph node recurrence or detectable prostate-specific antigen (PSA) (PSA >= 0.2 ng/mL, confirmed by a second PSA of the same level or higher), whichever occurs first, assessed up to 36 months
810 Total Participants · 2 Treatment Groups
Primary Treatment: Darolutamide · Has Placebo Group · Phase 3
Age 18+ · Male Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: